Weber Jan, Chakraborty Bikram, Weberova Jitka, Miller Michael D, Quiñones-Mateu Miguel E
Cleveland Clinic Foundation, Lerner Research Institute, Department of Molecular Genetics, Section Virology/NN10, 9500 Euclid Ave., Cleveland, OH 44195, USA.
J Clin Microbiol. 2005 Mar;43(3):1395-400. doi: 10.1128/JCM.43.3.1395-1400.2005.
The human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) resistance mutation K65R confers intermediate levels of resistance to several RT inhibitors, including a three- to fourfold reduction of tenofovir susceptibility. Here, we have used for the first time primary HIV-1 isolates from individuals who developed the K65R mutation while enrolled in a clinical trial of tenofovir to analyze the impact of this mutation on HIV-1 replicative fitness. A marked impairment in replicative fitness was observed in association with the selection of viruses carrying the K65R mutation in all patients. The mean replicative fitness among these viruses was 20% relative to the corresponding baseline wild-type virus, ranging from 10 to 32% depending on the accompanying RT mutations. These results support a reduction in in vivo replication for K65R mutant viruses.
1型人类免疫缺陷病毒(HIV-1)逆转录酶(RT)耐药突变K65R赋予对多种RT抑制剂的中等水平耐药性,包括使替诺福韦敏感性降低三到四倍。在此,我们首次使用来自在替诺福韦临床试验期间出现K65R突变的个体的原发性HIV-1分离株,来分析该突变对HIV-1复制适应性的影响。在所有患者中,与携带K65R突变的病毒选择相关联,观察到复制适应性显著受损。相对于相应的基线野生型病毒,这些病毒的平均复制适应性为20%,根据伴随的RT突变,范围在10%至32%之间。这些结果支持K65R突变病毒在体内复制减少。